8种抗组胺药治疗慢性荨麻疹的疗效和安全性网状Meta分析  

Efficacy and safety of 8 antihistamines for chronic urticaria:A network Meta-analysis

作　　者：陈思文 李湘鹏 许馥容 唐源苑 向丽萍[2] Chen Siwen;Li Xiangpeng;Xu Furong;Tang Yuanyuan;Xiang Liping(Hunan University of Chinese Medicine,Hunan 410208;The Second affiliated Hospital of Hunan University of Chinese Medicine,Hunan 410005)

机构地区：[1]湖南中医药大学,湖南410208 [2]湖南中医药大学第二附属医院,湖南410005

出　　处：《天津药学》2020年第2期40-44,共5页Tianjin Pharmacy

摘　　要：目的:运用网状Meta分析评估8种抗组胺药(左西替利嗪、依巴斯汀、氯雷他定、地氯雷他定、咪唑斯汀、奥洛他定、卢帕他定、非索非那定)治疗慢性荨麻疹的疗效和安全性。方法:在CNKI、Wanfang、CBM、PubMed、Embase上检索相关的随机对照试验,检索时间截至2019年12月,选择符合标准的文献,使用Stata 15.1和ADDIS 1.16.8软件进行网状Meta分析。结果:共纳入37篇文献,涉及4677例患者。网状Meta分析结果表明,依巴斯汀、地氯雷他定、咪唑斯汀的疗效均优于氯雷他定,8种抗组胺药之间的不良反应发生率无明显差异;概率排序图显示依巴斯汀治疗慢性荨麻疹的临床有效率最高(P=0.47)。结论:基于现有研究,依巴斯汀成为治疗慢性荨麻疹的最优选择的可能性最大,但本研究结论仍需更多高质量随机对照试验加以验证。Objective:To evaluate the efficacy and safety of eight antihistamines(levocetirizine,ebastine,loratadine,desloratadine,mizolastine,olopatadine,rupatadine,and fexofenadine)in the treatment of chronic urticaria by network metaanalysis.Methods:Relevant randomized controlled trials were searched on CNKI,Wanfang,CBM,PubMed,and Embase until December 2019,and articles that met the criteria were selected for network meta-analysis using Stata15.1 and ADDIS 1.16.8 software.Results:37 trials involving 4677 sufferers were included.The results of network meta-analysis showed that ebastine,desloratadine,and mizolastine were more effective than loratadine,and there was no significant difference in the incidence of adverse reactions among the 8 antihistamines;the probability ranking plot showed that ebastine had the highest clinical response rate in the treatment of chronic urticaria(P=0.47).Conclusion:Based on the available studies,ebastine has the greatest probability of being the best choice for the treatment of chronic urticaria,but the conclusions of this study still need to be verified by more high-quality RCTs.

关 键 词：抗组胺药 慢性荨麻疹 网状Meta分析 随机对照试验 

分 类 号：R986[医药卫生—药品]